|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1996-10-24
|
|
pubmed:abstractText |
We performed a prospective nonrandomized clinical trial to demonstrate that Interferon (IFN) treatment of individuals with chronic hepatitis C virus (HCV) positive hepatitis (CH-C) and serologic and/or histologic evidence of autoimmune dysregulation is feasible and whether the benefits of successfully treating CH-C are outweighed by the risk of exacerbating Autoimmune Chronic Active Hepatitis (ACAH).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0172-6390
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
900-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8847043-Antiviral Agents,
pubmed-meshheading:8847043-Autoantibodies,
pubmed-meshheading:8847043-Autoimmune Diseases,
pubmed-meshheading:8847043-Feasibility Studies,
pubmed-meshheading:8847043-Female,
pubmed-meshheading:8847043-Follow-Up Studies,
pubmed-meshheading:8847043-Hepatitis,
pubmed-meshheading:8847043-Hepatitis, Chronic,
pubmed-meshheading:8847043-Hepatitis C,
pubmed-meshheading:8847043-Humans,
pubmed-meshheading:8847043-Interferon-alpha,
pubmed-meshheading:8847043-Liver,
pubmed-meshheading:8847043-Male,
pubmed-meshheading:8847043-Middle Aged,
pubmed-meshheading:8847043-Prospective Studies,
pubmed-meshheading:8847043-Recombinant Proteins,
pubmed-meshheading:8847043-Risk Factors,
pubmed-meshheading:8847043-Time Factors
|
|
pubmed:articleTitle |
Interferon alpha treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation.
|
|
pubmed:affiliation |
Oklahoma Transplant Institute, Baptist Medical Center of Oklahoma, Oklahoma City, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
